NCT06340360 - A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 2, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

August 31, 2026

Conditions

Alopecia Areata

Interventions

DRUG

Rezpegaldesleukin

Pharmaceutical form: Injection solution Route of administration: subcutaneous

DRUG

Placebo

Pharmaceutical form: Injection solution Route of administration: subcutaneous

Trial Locations (28)

10075

Nektar Investigative Site, New York

17011

Nektar Investigative Site, Camp Hill

30331

Nektar Investigative Site, Atlanta

46202

Nektar Investigative Site, Indianapolis

48038

Nektar Investigative Site, Clinton Township

60031

Nektar Investigative Site, Gurnee

75034

Nektar Investigative Site, Frisco

78660

Nektar Investigative Site, Pflugerville

91324

Nektar Investigative Site, Northridge

03801

Nektar Investigative Site, Portsmouth

V3V 0C6

Nektar Investigative Site, Surrey

L3P 1X3

Nektar Investigative Site, Markham

L6J 7W5

Nektar Investigative Site, Oakville

L4B 1A5

Nektar Investigative Site, Richmond Hill

J1G 1X9

Nektar Investigative Site, Sherbrooke

60-185

Nektar Investigative Site, Skórzewo

50-450

Nektar Investigative Site, Wroclaw

50-566

Nektar Investigative Site, Wroclaw

51-685

Nektar Investigative Site, Wroclaw

67-100

Nektar Investigative Site, Nowa Sól

02-482

Nektar Investigative Site, Warsaw

02-956

Nektar Investigative Site, Warsaw

35-055

Nektar Investigative Site, Rzeszów

80-546

Nektar Investigative Site, Gdansk

40-611

Nektar Investigative Site, Katowice

41-200

Nektar Investigative Site, Sosnowiec

10-229

Nektar Investigative Site, Olsztyn

71-500

Nektar Investigative Site, Szczecin